Life360, Inc. — Director's Dealing 2022

Sep 15, 2022

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity:	Life360, Inc.
ARBN:	629 412 942

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

We (the entity) give ASX the following the director for the purposes of section	information under listing rule 3.19A.2 and as agent for 205G of the Corporations Act.
Name of Director	James Synge
Date of last notice	20 July 2022

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-
Date of change	8 September 2022 (PDT) (being 9 September 2022 AEST)
No. of securities held prior to change	 1,441,041 Chess Depositary Interests (CDIs)  16,887 Shares of Common Stock (Shares)(equivalent to 50,661 CDIs)  193,137 CDIs held by ICCA Labs, LLC1  211,720 CDIs held by Stynge Pty Ltd ATF Sandy Bay Trust.  4,581 Restricted Stock Units (RSUs)  33,972 Options over Shares (Options)

1 James Synge is a member of ICCA Labs, LLC, an entity that holds Life360 CDIs. The number of CDIs attributable to James Synge by reason of his membership interest in ICCA Labs, LLC is 193,137.

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

==> picture [434 x 342] intentionally omitted <==

----- Start of picture text -----

Class Shares and RSUs
Number acquired 1,145 Shares
Number disposed 1,145 RSUs (having vested)
Value/Consideration Shares are issued following the vesting and
Note: If consideration is non-cash, provide details and estimated valuation settlement of 1,145 RSUs which were
granted in lieu of the payment of Director
and Committee fees. [2]
No. of securities held after change  1,441,041 CDIs

18,032 Shares (equivalent to 54,096
CDIs)

193,137 CDIs held by ICCA Labs, LLC

211,720 CDIs held by Stynge Pty Ltd
ATF Sandy Bay Trust.
 3,436 RSUs
 33,972 Options
Nature of change Issue of shares following the vesting and
Example: on-market trade, off-market trade, exercise of options, settlement of RSUs.
issue of securities under dividend reinvestment plan, participation in
buy-back
----- End of picture text -----

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [434 x 219] intentionally omitted <==

----- Start of picture text -----

Detail of contract N/A
Nature of interest N/A
Name of registered holder N/A
(if issued securities)
Date of change N/A
No. and class of securities to which N/A
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired N/A
----- End of picture text -----

2 As per the Appendix 3Y lodged with the ASX on 27 May 2022, 4,581 RSUs were granted in lieu of the payment of US$37,500 of Director and Committee Fees.

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3